Salk Institute for Biological Studies:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Salk Institute for Biological Studies - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9312
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Salk Institute for Biological Studies (Salk) is a research institute that offers biological research programs. The institute’s areas of research comprise aging and regenerative medicine, cancer biology, immune system biology, metabolism and diabetes, neuroscience and neurological disorders, and plant biology. Its research provides development of new therapies and treatments for diseases such as cancer, AIDS, Alzheimer’s disease, cardiovascular disorders, anomalies of brain, birth defects, diabetes and metabolism, gene therapy, plant biology, vision, and williams syndrome, among others. Salk offers education outreach programs that deliver research impact on human health. The institute operates research centers such as Salk Cancer Center, Crick-Jacobs Center, Helmsley Center for Genomic Medicine, Center for the Neurobiology of Vision and Center for Nutritional Genomics, among others. Salk is headquartered in San Diego, California, the US.

Salk Institute for Biological Studies – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Salk Institute Enters into Agreement with Indivumed 10
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 11
Licensing Agreements 12
Metacrine Enters into Licensing Agreement with Salk Institute for Biological Studies 12
StemCell Technologies Enters into Licensing Agreement with Salk Institute for BrainPhys 13
Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 14
Salk Institute for Biological Studies – Key Competitors 15
Salk Institute for Biological Studies – Key Employees 16
Salk Institute for Biological Studies – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Government and Public Interest 18
Oct 02, 2018: Salk’s Janelle Ayres receives nih pioneer award for novel approaches to infectious disease 18
Sep 20, 2018: Decoding the structure of an RNA-based CRISPR system 19
Sep 18, 2018: Tweaking cells’ gatekeepers could lead to new way to fight cancer 20
Sep 13, 2018: Research in yeast leads to serendipitous finding about a central nervous system disorder 21
Sep 05, 2018: The alchemy of healing: Researchers turn open wounds into skin 22
Aug 30, 2018: A master switch controls aggressive breast cancer 23
Aug 23, 2018: Salk’s donors give $48.5 million to support scientific innovation in FY18 25
Aug 21, 2018: Salk Institute receives $2 million for cancer research initiative 26
Jul 11, 2018: Janelle Ayres receives $1 million from W. M. Keck Foundation for infectious disease research 27
Jun 26, 2018: Salk researchers win five competitive grants for cancer research 28
May 18, 2018: Salk Institute receives $1.5 million for Alzheimer’s research from NANOS 30
Mar 14, 2018: CRISPR genetic editing takes another big step forward, targeting RNA 31
Mar 13, 2018: Molecule That Gives Energy-Burning Brown Fat Its Identity Could Lead To Drugs For Obesity 33
Sep 19, 2017: CPRIT awards $34M to UTSW for cancer research recruitment 34
May 30, 2017: Brain’s immune cells linked to Alzheimer’s, Parkinson’s, schizophrenia 36
Feb 14, 2017: Salk scientist awarded inaugural Sjoberg Prize for cancer breakthrough 38
Other Significant Developments 39
Oct 18, 2018: Brain cells called astrocytes have unexpected role in brain plasticity 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Key Facts 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Salk Institute for Biological Studies, Deals By Therapy Area, 2012 to YTD 2018 8
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Salk Institute Enters into Agreement with Indivumed 10
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 11
Metacrine Enters into Licensing Agreement with Salk Institute for Biological Studies 12
StemCell Technologies Enters into Licensing Agreement with Salk Institute for BrainPhys 13
Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 14
Salk Institute for Biological Studies, Key Competitors 15
Salk Institute for Biological Studies, Key Employees 16

List of Figures
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Salk Institute for Biological Studies:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Martindale Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Martindale Pharmaceuticals Ltd (Martindale), a subsidiary of Cardinal Health Inc is a pharmaceutical company that offers formulations. The company provides hospital-initiated medicines in emergency medicine and differentiated products in complex neurological conditions,opioid addiction and p …
  • Alfred E. Tiefenbacher GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報
    Summary Alfred E. Tiefenbacher GmbH & Co KG (AET) is an independent pharmaceutical company that focuses on the development of active pharmaceuticals ingredients. It offers products in the forms of tablets, capsules, oral solution, patches, long acting injectables, ophthalmic solution and inhaled the …
  • University of New Mexico:製薬・医療:M&Aディール及び事業提携情報
    Summary University of New Mexico (UNM) is an educational service provider that offers bachelors, masters, doctoral and professional degree programs in various fields. The university offers programs such as evening and weekend degree programs, continuing education, extended learning, Latin American s …
  • Kongsberg Maritime AS:企業の戦略的SWOT分析
    Kongsberg Maritime AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Suven Life Sciences Ltd (SUVEN):企業の財務・戦略的SWOT分析
    Summary Suven Life Sciences Ltd (Suven) formerly Suven Pharmaceuticals Pvt Ltd designs, develops, manufactures and supplies bulk actives, drug intermediates and fine chemicals. The company offers active pharmaceutical ingredient products which include aripiprazole, calcium acetate, divalproex sodium …
  • Ben E. Keith Co:企業の戦略的SWOT分析
    Ben E. Keith Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Puma Energy Holdings Pte Ltd:企業のM&A・事業提携・投資動向
    Puma Energy Holdings Pte Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Puma Energy Holdings Pte Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Radiomedix Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Radiomedix Inc (Radiomedix) is a biotechnology company that develops and commercializes radiopharmaceuticals for diagnosis and therapy of cancer. The company’s products include radioisotopes, fully automated synthesizers, semi-automated synthesizers, GMP cassettes and consumables, smartmedix …
  • GN Hearing AS:医療機器:M&Aディール及び事業提携情報
    Summary GN Hearing AS (GN Hearing) formerly, GN ReSound A/S, a subsidiary of GN Store Nord A/S, is a medical equipment company that provides advanced hearing health care solutions. The company offers hearing aids, accessories and related products. It also supplies computerized audiology and hearing …
  • Kirayaka Bank, Ltd.:企業の戦略・SWOT・財務情報
    Kirayaka Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kirayaka Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • EPI Ingredients:企業の戦略・SWOT・財務分析
    EPI Ingredients - Strategy, SWOT and Corporate Finance Report Summary EPI Ingredients - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Technology Nexus AB:企業の戦略的SWOT分析
    Technology Nexus AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Dynatronics Corp (DYNT):企業の財務・戦略的SWOT分析
    Summary Dynatronics Corp (Dynatronics) is a medical device company that offers physical therapy, aesthetics and medical products. The company offers hot and cold therapy, clinical accessories, body positioning, sports medicine, orthopedics, hand therapy, strength equipment, treatment tables and reha …
  • Nuclear Power Corporation of India Ltd:企業の戦略的SWOT分析
    Nuclear Power Corporation of India Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Reliance Insurance Limited:企業の戦略・SWOT・財務情報
    Reliance Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Cosan S.A. Industria e Comercio (CSAN3):企業の財務・戦略的SWOT分析
    Cosan S.A. Industria e Comercio (CSAN3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Artes Biotechnology GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Artes Biotechnology GmbH (ARTES) is a developer of recombinant production cell lines and processes that is based on the microbial expression platforms. The company offers biosimilars, enzymes and proteins and vaccines. It offers technology transfer and implementation support, protein analyti …
  • Agfa HealthCare NV-医療機器分野:企業M&A・提携分析
    Summary Agfa HealthCare NV (Agfa HealthCare) a subsidiary of Agfa-Gevaert NV is a healthcare technology company that develops, produces and distributes analog and digital imaging systems and information technology solutions. The company operates through diagnostic imaging, enterprise imaging, integr …
  • Marubeni Corporation (8002)-石油・ガス分野:企業M&A・提携分析
    Summary Marubeni Corporation (Marubeni) is an integrated trading and investment business that operates through its domestic and overseas subsidiaries. It provides various products and commodities such as agri and marine products, chemicals, energy, metals and minerals, machinery, textiles, forest pr …
  • Royal Dutch Shell Plc (RDSA)-エネルギー分野:企業M&A・提携分析
    Summary Royal Dutch Shell plc (Shell) is an integrated oil and gas company. The company explores for and produces oil and gas from conventional fields and sources such as tight rock, shale and coal formations. Its refining and petrochemical complexes across the world add value to its upstream produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆